ArticleCureus2025
Severe Warm Autoimmune Hemolytic Anemia With Anti-PO Antibody Positivity: A Diagnostic Dilemma in a Resource-Limited Setting.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a diagnostically challenging case of a 45-year-old woman with severe anemia (Hemoglobin: 2.9 g/dL) and laboratory evidence of hemolysis. She was found to have positive anti-PO, anti-Ku, and anti-U1snRNP antibodies, raising suspicion for an autoimmune etiology such as systemic lupus erythematosus (SLE). However, this case did not fulfill the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 or Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria due to the absence of antinuclear antibodies (ANA) by indirect immunofluorescence (IIF) and incomplete immunological testing. The patient responded to packed red blood cell (PRBC) transfusions, corticosteroids, and a single dose of rituximab. This case highlights diagnostic complexity in autoimmune presentations, especially in resource-constrained settings, and emphasizes caution in interpreting rare autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.